Clinical Trial Update: Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 safety and pharmacology study of SNX-5422 in patients with refractory hematologic malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma

Drugs mentioned

• SNX-5422

Snippet

Sponsor: Esanex Inc. | Conditions: Cancer | Phase 1 | Status: COMPLETED